Trials / Terminated
TerminatedNCT00425919
Study Evaluating PPM-204 In Subjects With Type 2 Diabetes
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.
Detailed description
The objectives of the study are to identify doses of PPM-204 that are therapeutically effective and well tolerated in improving glycemic control over 24 weeks of treatment in subjects with type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PPM-204 |
Timeline
- Start date
- 2007-01-01
- Completion
- 2007-10-01
- First posted
- 2007-01-23
- Last updated
- 2007-12-27
Locations
68 sites across 18 countries: United States, Argentina, Australia, Brazil, Canada, China, Croatia, Greece, Hong Kong, India, Italy, Mexico, Romania, Russia, Serbia and Montenegro, South Africa, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00425919. Inclusion in this directory is not an endorsement.